Recent News

• 03.10.2026 - Seralutinib disminuye la producción de endotrofina (PRO-C6), un mediador de fibrosis e inflamación
• 03.10.2026 - Seralutinib preserva función pulmonar y actividad antifibrótica en modelos de fibrosis pulmonar
• 03.10.2026 - Seralutinib: efectos antifibróticos significativos y evidencia de modelos derivados de pacientes
• 03.10.2026 - Seralutinib aumenta volumen arterial pulmonar y reduce remodelado vascular: análisis por TC con IA
• 03.10.2026 - Seralutinib en HAP: explorando mecanismos de remodelado inverso versus vasodilatacion
• 01.30.2026 - Seralutinib demonstrated in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
• 01.30.2026 - Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
• 01.29.2026 - Seralutinib targets fibrotic pathways in IPF: Evidence from single-cell transcriptomics
• 01.29.2026 - Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
• 01.29.2026 - Trial in progress: SERANATA, a phase 3 randomized, placebo-controlled trial to evaluate inhaled seralutinib for treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Recent Filings

• 03.02.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.24.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.23.2026 - EX-99.1 EX-99.1
• 02.23.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.28.2026 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities